A Prophylaxis Choice Shaped by a Disease It Isn't
A single patient whose family history quietly reframes which drug family her prophylaxis should come from. The disagreement is about how much weight a real but circumstantial history should carry against a drug's own disease-specific track record.
N.B., a 22-year-old graduate student in mechanical engineering, has had episodes of severe, stereotyped vomiting since her early teens — sudden onset, several days of relentless nausea and vomiting requiring IV fluids more than once, followed by complete return to baseline health, with clean intervals sometimes lasting months. The pattern finally earned a formal diagnosis of cyclic vomiting syndrome last year after years of being told, at various points, that it was probably anxiety, probably a stomach virus that kept recurring, or probably nothing structural worth pursuing further. What made the diagnosis click for her new gastroenterologist was something her family had mentioned almost in passing: her mother has migraines, and N.B. herself had motion sickness and abdominal migraine as a child, both real, if underappreciated, threads in her history.
Cyclic vomiting syndrome and migraine share more than superficial resemblance — both are increasingly understood to involve related pathophysiology, including mitochondrial dysfunction and a shared genetic and familial predisposition, which is why her mother's migraine history and her own childhood abdominal migraine aren't incidental details but part of the actual diagnostic picture. That overlap is also what shapes prophylactic drug selection: rather than one obvious first-line agent, two genuinely different pharmacologic families have real evidence behind them, chosen partly by which pathway a clinician reads her family history as pointing toward.
Amitriptyline, a tricyclic antidepressant acting through combined serotonergic and noradrenergic reuptake inhibition, has the longest track record as first-line CVS prophylaxis in both pediatric and adult literature — named as such in the ANMS/CVSA adult guideline (Venkatesan and colleagues), building on Prakash and Clouse's original description of adult CVS and its response to tricyclics — effective independent of any confirmed migraine link. Topiramate and propranolol, both established migraine-preventive agents, offer a more mechanistically direct rationale specifically because of the migraine-CVS overlap her own family and childhood history support — treating the disease as functionally migraine-adjacent rather than as its own unrelated entity. Four to six episodes a year, each requiring IV fluids and each disrupting a semester's worth of coursework and exams, is also the number both physicians keep returning to when talking through what "adequate response" would actually need to look like — a real reduction in frequency, not simply a milder average episode.
Choosing a prophylactic agent between two real evidence bases
Her family history isn't incidental — a mother with migraines and her own childhood abdominal migraine and motion sickness are concrete, real findings, and the overlap between cyclic vomiting syndrome and migraine pathophysiology, including shared mitochondrial and genetic threads, is increasingly well supported.
I'd start topiramate rather than propranolol specifically — propranolol's exercise-tolerance and mood-related side effects are a real concern for someone managing a demanding graduate program and an active routine, where topiramate's side-effect profile is more favorable for her specifically.
I don't doubt the migraine overlap is real, and her history genuinely fits the pattern.
What I'd weigh against starting there is that amitriptyline has the longest and most CVS-specific track record in the literature, effective in both pediatric and adult cohorts independent of any confirmed migraine mechanism. It doesn't ask us to be right about whether her CVS is migraine-pathophysiology-driven for the choice to be justified — it has its own direct evidence base for this exact diagnosis.
That's a genuinely fair point — amitriptyline's evidence doesn't depend on the migraine-overlap theory being correct, and I'd rather defer to the disease-specific literature than push a mechanistically appealing but less directly tested option as the very first trial.
I'd support starting amitriptyline first, with topiramate named explicitly as the next step if episode frequency doesn't improve meaningfully — her family history stays relevant to that second decision even if it isn't the deciding factor for the first one.
Amitriptyline started at a low, titrated dose as first-line prophylaxis, with topiramate named explicitly in her chart as the next step if episode frequency doesn't meaningfully improve, rather than left as an open-ended alternative.
Genuinely reconciled through the discussion itself — the Neurologist's reading of her family history shaped the sequencing plan even though amitriptyline's own direct evidence base carried the first choice.